• CB-13 is designed to stay largely outside the blood–brain barrier, providing peripheral CB₁/CB₂ activity (analgesia, anti-inflammatory) with greatly reduced central psychoactivity.
• Recreational 'high' is weak or absent below very large doses; most user reports describe mild body relaxation, analgesia and sleepiness rather than classic cannabis effects.
• Because effective doses are hundreds of milligrams orally, material cost, impurities and liver load become significant concerns.
• Limited human data – no formal safety studies. Start with allergy test (<5 mg vaped or <25 mg oral).
• May cause dose-dependent hypotension, tachycardia, dry mouth, nausea, and impaired motor coordination. Very high doses in rodents produced hypothermia and catalepsy.
• Avoid driving for at least 6 h after use.
• Being peripherally restricted does NOT guarantee absence of central effects if very large doses are taken or if the blood–brain barrier is compromised (e.g., by alcohol or inflammation).
Also known as: Cra-13, Sab-378
Classification
Chemical: Cannabinoid
Psychoactive: Depressant
Tag: Habit-Forming
Tag: Hallucinogen
Tag: Naphthalene derivative
Tag: Research-Chemical
Effects
Mild Body Euphoriarelaxation
Analgesia
Anxiolysis
Sedationdrowsiness
Dry Mouth
Reddened Eyes
Anxiety Suppression
Drowsiness
Reduced Anxiety
Euphoria
Time Distortion
Anxiety
Warmthtingling
Dulled Perception
Internal Hallucination
External Hallucination
Auditory Hallucination
Drifting
Routes of Administration
Oral
Dosage
Threshold: 50 mg
Light: 75 – 150 mg
Common: 150 – 300 mg
Strong: 300 – 450 mg
Heavy: 450 mg + (not recommended)
Duration
Onset: 0.5-1.5 h
Peak: 2-4 h
Offset: 2-4 h
After Effects: 2-6 h
Total Duration: 6-10 h
Vaporized
Dosage
Threshold: 5 mg
Light: 10 – 15 mg
Common: 15 – 30 mg (inefficient)
Strong: 30 – 50 mg
Heavy: > 50 mg (little additional effect)
Duration
Onset: 0.02-0.08 h
Peak: 0.5-1.5 h
Offset: 1-2 h
After Effects: 2-6 h
Total Duration: 3-5 h
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
This static page is intended as a readable non-JS and prerender-friendly library export.
Get the full DrugsPRO experience
Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.
Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu
CB-13 - DrugsPRO substancijos vadovas
CB-13: • CB-13 is designed to stay largely outside the blood–brain barrier, providing peripheral CB₁/CB₂ activity (analgesia, anti-inflammatory) with greatly reduced central psychoactivity.
• Recreational 'high' is weak or absent below very large doses; most user reports describe mild body relaxatio
